Publication Name	World Journal of Diabetes
Manuscript ID	89337
Country	United Kingdom

Received	2023-10-28 21:04
Peer-Review Started	2023-10-28 21:04
First Decision by Editorial Office Director	2023-12-29 06:47
Return for Revision	2023-12-29 06:47
Revised	2024-01-02 06:54
Publication Fee Transferred
Second Decision by Editor	2024-02-05 10:42
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-02-18 08:22
Articles in Press	2024-02-18 08:22
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-02-29 02:14
Publish the Manuscript Online	2024-03-15 09:49

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Observational Study
Article Title	Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience
Manuscript Source	Invited Manuscript
All Author List	Lubna Islam, Dhanya Jose, Mohammed Alkhalifah, Dania Blaibel, Vishnu Chandrabalan and Joseph M Pappachan
Funding Agency and Grant Number
Corresponding Author	Joseph M Pappachan, FRCP, MD, Academic Editor, Consultant Physician-Scientist, Professor, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Key Words	Sodium glucose cotransporter-2 inhibitors; Empagliflozin; Canagliflozin; Dapagliflozin; Type 2 diabetes mellitus; Cardiovascular disease; Albumin creatinine ratio; Diabesity
Core Tip	Treatment of type 2 diabetes mellitus with sodium glucose cotransporter-2 inhibitors (SGLT-2i) is associated with significant glycated hemoglobin (HbA1c) reduction, body weight loss, and cardiovascular benefits as proven by multiple randomised controlled trials (RCTs). Our real-world data analysis of the efficacy and safety of individual SGLT-2i revealed better reduction of HbA1c with dapagliflozin, canagliflozin, and empagliflozin, while better body weight reduction was seen only with dapagliflozin and canagliflozin when compared to RCTs. Blood pressure reduction, and side effect profiles were comparable to previous studies. A significant improvement of albuminuria was obvious only with canagliflozin, presumably because of the low number of participants in this study. Analyses of various large-scale real-world data are expected to inform better clinical decision making in future.
Publish Date	2024-03-15 09:49
Citation	Islam L, Jose D, Alkhalifah M, Blaibel D, Chandrabalan V, Pappachan JM. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience. World J Diabetes 2024; 15(3): 463-474
URL	https://www.wjgnet.com/1948-9358/full/v15/i3/463.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i3.463

Full Article (PDF)	WJD-15-463-with-cover.pdf
Full Article (Word)	WJD-15-463.docx